CASRAI Dictionary

Tag: mCTA

  • Model Clinical Trial Agreement UK Guide (2026)

    The UK Model Clinical Trial Agreement (mCTA) is the standard contract template that commercial sponsors and NHS or HSC organisations use to set up an industry-sponsored clinical trial, published and maintained via the Health Research Authority’s IRAS toolkit, and required to be used unmodified in almost all cases across England, Scotland, Wales and Northern Ireland. The model clinical trial agreement UK framework now covers seven distinct template families, from the core mCTA to devices, primary care and non-commercial variants, and the whole suite was refreshed on 28 April 2026.

    In plain terms: the mCTA is a UK-wide, sector-agreed contract — not a bespoke negotiation — that fixes the legal, indemnity and financial terms between a trial sponsor (or its contract research organisation) and each participating NHS or HSC site, so that individual hospitals and trusts do not have to negotiate contract wording study by study.

    What is the UK Model Clinical Trial Agreement (mCTA)?

    The mCTA is the default site agreement for commercial, industry-sponsored clinical trials of investigational medicinal products (CTIMPs) run in NHS and HSC organisations. It sits alongside a wider family of UK model agreements covering devices, primary care, non-interventional studies and non-commercial research, all hosted on the Integrated Research Application System (IRAS) website.

    Under the current suite, published for use from 28 April 2026, the seven core template families are:

    Template Typical use case Current version
    mCTA / CRO-mCTA Industry-sponsored CTIMP trials in NHS/HSC hospitals April 2026
    ATMP-mCTA / CRO-ATMP-mCTA Trials of investigational advanced therapy medicinal products April 2026
    Primary care mCTA (bi- and tri-partite) Industry trials run through GP practices and other primary care sites April 2026
    mCIA / CRO-mCIA Commercial medical device clinical investigations April 2026
    mNISA / CRO-mNISA Commercial non-interventional studies April 2026
    mNCA Non-commercial interventional research (trials, devices, tissue, data) April 2026
    mCCIA / CRO-mCCIA Contracting an NHS/HSC employee as Chief Investigator April 2026

    Each template is designed to be used without alteration, with only the yellow-highlighted, study-specific fields completed. This is what allows an mCTA-based site agreement to be executed in days rather than the weeks or months a fully bespoke contract typically takes to negotiate clause by clause.

    ABPI model clinical trial agreement vs HRA model clinical trial agreement

    Sponsors and R&D teams search for both the “ABPI model clinical trial agreement” and the “HRA model clinical trial agreement” — but these are not two competing templates. They are the same lineage of document, described by its origin on one hand and its current steward on the other.

    The original CRO-mCTA guidance describes how the tripartite template was developed jointly as the “NHS-ABPI-BIA Contract Research Organisation model Clinical Trial Agreement”, reflecting the historic partnership between the NHS, the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA). That is why many sponsors still call it the “ABPI mCTA” out of habit.

    Today, the templates are published, version-controlled and hosted through the Health Research Authority’s IRAS toolkit, and governed by the UK Four Nations Contracting Leads Group, which reviews user feedback and decides on revisions roughly every six months. That governance and hosting arrangement is why the same document is now more accurately described as the “HRA model clinical trial agreement”. There is one current mCTA family, not a rival ABPI version and a rival HRA version to choose between.

    When to use the unmodified mCTA vs a bespoke agreement

    For nearly all commercial contract research, the unmodified UK template is mandatory, not optional. Under the National Directive on Commercial Contract Research, HRA and Health and Care Research Wales (HCRW) Approval is normally issued conditionally on the appropriate, unaltered template being used, and each devolved nation applies an equivalent policy position.

    A bespoke or modified agreement is reserved for genuinely exceptional circumstances, primarily where no UK template exists for the specific project type. Sponsors who want to depart from the standard template must:

    • Submit a formal waiver request to the HRA and HCRW, usually as part of the Approval conditions
    • Set out any proposed changes clearly in the IRAS cover letter, with a tracked-change version of the template
    • Provide a detailed, change-by-change rationale for each deviation

    The HRA is explicit that a waiver request is “liable to add many months of central negotiation” and is unlikely to be agreed. Even where a waiver is granted, it only removes the obligation on participating NHS or HSC organisations to accept the unmodified template — individual sites remain free to propose their own terms or seek independent legal advice at the sponsor’s expense. For non-commercial research there is no equivalent statutory directive, but the same policy expectation applies: use the appropriate UK template (typically the mNCA) unmodified, or expect a prolonged review.

    How the HRA and IRAS toolkit route studies to the right template

    Sponsors do not have to guess which agreement applies. For studies going through HRA and HCRW Approval, the HRA Initial Assessment Letter and the subsequent Approval letter specify the correct agreement for each participating site type — whether that is an unmodified mCTA variant or an Organisation Information Document for non-commercial studies.

    Two toolkits sit either side of that decision:

    • The IRAS website (myresearchproject.org.uk) hosts the live template documents, version-dated guidance notes, and the definitive “Templates for supporting documents” index used to download the correct .docx file
    • The Clinical Trials Toolkit (ct-toolkit.ac.uk), a UKCRC-supported routemap, walks research teams through the contracting decision points step by step, from identifying sponsorship type to selecting the matching agreement

    Where a study uses a hub-and-spoke delivery model, a further layer applies: the Lead Trial Site contracts with the sponsor via an unaltered mCTA or mNCA, and then a UK template Hub and Spoke Agreement subcontracts rights and responsibilities down to each Other Trial Site. Feedback on any template is directed to the Four Nations Contracting Leads Group via [email protected], and any new studies submitted in IRAS on or after 28 April 2026 must use the April 2026 versions — earlier versions are no longer accepted.

    Frequently asked questions

    What is a clinical trial agreement?

    A clinical trial agreement is a legally binding contract between a trial sponsor, a research site and (in some templates) the principal investigator, setting out each party’s responsibilities, indemnities and financial terms for a specific study. In the UK, most industry-sponsored trials use a standard mCTA rather than a one-off negotiated contract.

    What is the NHS model CDA?

    The model Confidentiality Disclosure Agreement (mCDA) is a separate UK-wide template used earlier in study set-up, before a site agreement such as the mCTA is signed. It governs the sharing of confidential feasibility information between a sponsor and prospective NHS or HSC sites, and — like the mCTA — is expected to be used unaltered.

    Implications and outlook for sponsors and R&D offices

    The practical implication for institutional research offices is straightforward: default to the unmodified template every time, budget waiver requests as a last resort measured in months rather than weeks, and rebuild any local contract-tracking spreadsheets around the April 2026 version numbers so that expired templates are not accidentally resubmitted through IRAS.

    Because the Four Nations Contracting Leads Group reviews feedback and revises the suite roughly twice a year, sponsors and R&D offices operating in research administration functions should treat the mCTA suite as a living document set, not a one-off download, and check the IRAS templates page before every new study submission rather than relying on a cached copy from a previous trial.

  • Clinical Trial Agreements Explained: Structure, Parties and Sign-Off

    A clinical trial agreement (CTA) is the legally binding contract that fixes how a trial will run, who pays for what, who owns any resulting intellectual property, and who carries liability if something goes wrong. It is negotiated between the sponsor (or its contract research organisation) and the research site, and it must be fully executed before the first participant is recruited.

    A clinical trial agreement is the contract that allocates the legal, financial and operational responsibilities for conducting a specific clinical study between a sponsor and a research institution or investigator. Research administrators new to clinical contracting encounter the CTA as the single document that everything else — costings, indemnity cover, publication clearance, data ownership — hangs off.

    What is a clinical trial agreement?

    A clinical trial agreement is a written contract, not a protocol or an ethics approval. It sits alongside — but is legally distinct from — the study protocol, the participant information sheet, and any regulatory or ethics sign-off. Its function is purely contractual: it converts the scientific plan for a trial into binding obligations that a court could enforce.

    Every jurisdiction that runs interventional trials of medicinal products requires one. In the UK, a CTA (or its non-commercial equivalent) must be in place before a site can open to recruitment under the UK Clinical Trials Regulations, and the Health Research Authority treats a missing or incomplete agreement as a start-up blocker, not a formality to be finished later.

    Who are the parties to a clinical trial agreement?

    Most CTAs involve three or four distinct parties, each with a different legal interest in the trial. The sponsor initiates, funds and takes overall responsibility for the trial; the research site (a hospital, university, or NHS trust) hosts the study and employs the staff who run it; and the principal investigator is the named clinician or academic accountable for day-to-day conduct at that site.

    • Sponsor — a pharmaceutical, biotech or medical device company, or an academic institution acting as sponsor for investigator-led research.
    • Contract research organisation (CRO) — frequently contracted by the sponsor to manage set-up, monitoring and payments; in tripartite UK model agreements, the CRO can be a direct signatory alongside the sponsor and the site.
    • Research site / host institution — the legal entity (NHS trust, university, or independent hospital) that signs on behalf of the department running the study.
    • Principal investigator — named in the agreement but usually not a contracting party in their personal capacity; their obligations run through their employing institution.

    The CITI Program summarises the arrangement precisely: a CTA “serves as a legally binding contract between a sponsor, site, and researcher, and outlines each party’s responsibilities and obligations for the clinical trial.”

    What clauses does a clinical trial agreement cover?

    A CTA is built from a fixed set of recurring clauses, and administrators new to the process should expect negotiation to concentrate almost entirely on four of them: indemnity, intellectual property, publication rights, and data/record access. The rest are usually more mechanical.

    Clause What it fixes Typical friction point
    Indemnity and insurance Who compensates whom for harm, negligence, or breach Sponsor indemnity wording vs institutional NHS indemnity schemes
    Intellectual property Ownership of background IP vs new inventions arising from the trial Background IP retained by originating party; foreground IP terms vary by contract type
    Publication rights When and how results may be published or presented Sponsor review period vs researcher’s right to publish negative results
    Confidentiality Protection of proprietary protocols, data and trial materials Duration of confidentiality obligations after trial closure
    Financial terms Budget, payment schedule, and cost recovery Per-patient costs vs milestone-linked payment triggers
    Data and record-keeping Access, retention and audit rights over trial records Regulatory retention periods vs institutional data-governance policy
    Subject injury Care and compensation for participants harmed by the trial Allocation of liability between sponsor and clinical negligence cover

    Peer-reviewed research backs up why these clauses matter operationally, not just legally: a quantitative study published via Cambridge Core (Lawrence et al.) found that standardised agreement templates measurably reduce multisite trial start-up time compared with bespoke, clause-by-clause negotiation.

    Commercial CTA or non-commercial agreement — which applies?

    Which template an administrator reaches for depends on who is funding the trial, not on the disease area or design. This distinction is UK-specific but the underlying logic — industry-funded work uses a different contracting route to grant-funded academic work — recurs across most national research systems.

    Feature Model Clinical Trial Agreement (mCTA) Model Non-Commercial Agreement (mNCA)
    Funder Pharmaceutical, biotech or device company Grant body, charity, or NIHR/UKRI funding
    Publisher ABPI / HRA UK-wide model suite UK-wide non-commercial model agreement suite
    IP default position Sponsor typically retains foreground IP Host institution typically retains IP
    Common signatories Sponsor, CRO, NHS trust Funder, NHS trust, sometimes co-sponsoring university

    The Health Research Authority confirmed on 28 April 2026 that it had issued an updated suite of UK model agreements to reflect changes to the UK Clinical Trials Regulations, covering both commercial and non-commercial templates. The NIHR confirms that model agreements are one of the UK-wide tools institutions use alongside the National Contract Value Review when setting per-patient trial costs. The Association of the British Pharmaceutical Industry separately maintains a tripartite Model Generic Clinical Trial Agreement for industry-sponsored research delivered through NHS hospitals and managed by CROs.

    How is a CTA negotiated and signed off?

    Sign-off follows a predictable sequence: the sponsor or CRO issues a draft (usually a model agreement where one applies), the institution’s research and innovation office reviews it against institutional policy, legal counsel on both sides negotiate the contested clauses, and the agreement is executed by an authorised signatory at the institution — rarely the investigator personally.

    • Draft issued, typically based on a national model template where the funder type allows it.
    • Institutional review against local indemnity, IP and data-governance policy.
    • Negotiation of contested clauses — indemnity and publication rights are the most common sticking points.
    • Legal execution by the institution’s authorised signatory, not the principal investigator.
    • Filing alongside ethics approval and regulatory documentation before site activation.

    Using an unamended model agreement removes most of this negotiation entirely, which is precisely why the HRA and NIHR continue to maintain and update the UK-wide model suite rather than leaving every trial to bespoke drafting.

    Common questions on clinical trial agreements

    What is a clinical trials agreement?

    A clinical trials agreement is a legally binding contract between a sponsor, a research site and an investigator that fixes each party’s responsibilities before a study begins. It covers funding, indemnity, intellectual property, publication rights and data access, and must be executed before recruitment starts.

    What is the difference between a CTA and a CRA?

    A CTA (clinical trial agreement) is the contract governing a study; a CRA (clinical research associate) is a person who monitors trial conduct and compliance at sites. One is a legal document; the other is a job role responsible for oversight and monitoring within the trial.

    Who develops the clinical trial agreement?

    The sponsor or its CRO typically issues the first draft, often a national model agreement where one is available for the funding type. The host institution’s research office and legal counsel then negotiate amendments before an authorised institutional signatory executes the final version.

    What this means for research administrators

    The direction of travel in the UK is towards standardisation, not bespoke drafting. The HRA’s April 2026 update to the model agreement suite, and the NIHR’s continued linkage of model contracts to the National Contract Value Review, push institutions towards unamended templates as the default and bespoke drafting as the justified exception.

    The practical takeaway: identify the funding type first — commercial sponsor versus non-commercial funder — before selecting a template, route indemnity and publication-rights clauses to legal review early, and treat the CTA as a live governance document, filed and retrievable alongside ethics approval for the trial’s life, not a one-off signing formality.

    The CTA sits within a wider set of research administration obligations spanning ethics, finance and compliance sign-off — treating it in isolation from that broader governance process is the most common source of late-stage delay.